The QCDx mission is to deliver sensitive and specific detection of rare cells for precision disease diagnosis. A next generation, world-best liquid biopsy for precision diagnosis of cancer will offer detection and deep characterization of Circulating Tumor Cells (CTCs) for early cancer diagnosis, monitoring of treatment efficacy and surveillance for disease recurrence.
The proprietary RareScope™ is designed to analyze intact cell suspensions for sensitive detection of CTC phenotypes from the epithelial to mesenchymal spectrum and characterize for biomarkers related to targeted therapy or immunotherapy. It also offers isolation of detected CTCs for downstream molecular analysis to inform on precision treatment options. It will also analyze ex vivo, the effect of bioactive substances (including cancer drugs) on detected CTCs, to deliver on unmet need for optimal drug selection, before treatment is administered to the patient.
Company Details
- Employees
- 24
- Founded
- -
- Address
- 400 Farmington Ave.,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.qcd-x.com
- HQ
- Farmington, CT
Qcdx Questions
Qcdx's website is http://www.qcd-x.com
Qcdx's LinkedIn profile is https://www.linkedin.com/company/qcdx
Qcdx has
24 employees.
View email and phone details for 24
employees at Qcdx.
Qcdx's industry is
Biotechnology Research
Qcdx's top competitors are
Ikonisys,
Rnaconnect,
Immunespec,
Bioct,
Proteowise,
Bastion Health,
Cytoveris,
Ancera,
Pillar Biosciences Incorporated,
Pictor.
Qcdx's categories are Biotechnology Research
Qcdx's founding year is 2017
